Education
About Us
Working with TipRanks
Follow Us
Achieve Life Sciences Inc (ACHV)
NASDAQ:ACHV
ACHV Stock Chart & Stats
$4.45
-$0.11(-3.08%)
At close: 4:00 PM EST
$4.45
-$0.11(-3.08%)
Day’s Range― - ―
52-Week Range$1.84 - $5.78
Previous CloseN/A
Volume131.37K
Average Volume (3M)1.85M
Market Cap
$244.34M
Enterprise Value$122.55M
Total Cash (Recent Filing)$48.11M
Total Debt (Recent Filing)$9.96M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Mar 12, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding53,233,990
10 Day Avg. Volume901,639
30 Day Avg. Volume1,848,064
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)5.40
Price to Sales (P/S)0.00
P/FCF Ratio-3.79
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.05K
Enterprise Value/Ebitda-2.37
Forecast
1Y Price Target
$14.60Price Target Upside228.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.18
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsCytisinicline demonstrated positive results in the P3 ORCA-2 study, achieving significant rates of smoking cessation compared to placebo without serious treatment-related adverse events.
Market OpportunityLabel expansion focused on e-cigarette cessation represents a unique commercial opportunity that will substantially boost cytisinicline's use in key markets.
Regulatory ApprovalAchieve Life Sciences received an FDA Commissioner's National Priority Voucher for cytisinicline in e-cig/vaping cessation, allowing for expedited FDA review and potential earlier market entry.
Bears Say
Execution And Regulatory RisksRisks to the thesis include commercial execution risk, clinical trial risk, regulatory risk, financing risk, and the potential need for a partner.
Financial LossesAchieve Life Sciences reported a net loss of $14.4M for 3Q25, which may concern some investors despite other positive developments.
Achieve Life Sciences News
ACHV FAQ
What was Achieve Life Sciences Inc’s price range in the past 12 months?
Achieve Life Sciences Inc lowest stock price was $1.84 and its highest was $5.78 in the past 12 months.
What is Achieve Life Sciences Inc’s market cap?
Achieve Life Sciences Inc’s market cap is $244.34M.
When is Achieve Life Sciences Inc’s upcoming earnings report date?
Achieve Life Sciences Inc’s upcoming earnings report date is Mar 12, 2026 which is in 119 days.
How were Achieve Life Sciences Inc’s earnings last quarter?
Achieve Life Sciences Inc released its earnings results on Nov 06, 2025. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.244 by -$0.036.
Is Achieve Life Sciences Inc overvalued?
According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued.
Does Achieve Life Sciences Inc pay dividends?
Achieve Life Sciences Inc does not currently pay dividends.
What is Achieve Life Sciences Inc’s EPS estimate?
Achieve Life Sciences Inc’s EPS estimate is -0.27.
How many shares outstanding does Achieve Life Sciences Inc have?
Achieve Life Sciences Inc has 53,233,990 shares outstanding.
What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?
Achieve Life Sciences Inc reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.244. Following the earnings report the stock price went down -3.854%.
Which hedge fund is a major shareholder of Achieve Life Sciences Inc?
Currently, no hedge funds are holding shares in ACHV
Achieve Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.60 (228.09% Upside)
$14.60 (228.09% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 75%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.88%
12-Months-Change
Fundamentals
Return on Equity
-161.08%
Trailing 12-Months
Asset Growth
8.60%
Trailing 12-Months
Company Description
Achieve Life Sciences Inc
Achieve Life Sciences, Inc. (ACHV) is a clinical-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction. Operating primarily within the biopharmaceutical sector, the company's core focus is on addressing the global smoking health crisis by providing an alternative to existing smoking cessation therapies.
ACHV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant regulatory achievements and strategic advancements, particularly in gaining an expedited review for vaping cessation. However, funding needs for further clinical trials and challenges in aligning commercial strategies for two different market entries pose potential risks.View all ACHV earnings summariesACHV Stock 12 Month Forecast
Average Price Target
$14.60
▲(228.09% Upside)
Technical Analysis
Ownership Overview
1.75% Insiders
8.35% Mutual Funds
0.02% Other Institutional Investors
83.78% Public Companies and Individual Investors